RVMD Begins Phase 3 Trial
Revolution Medicines starts treating patients in a Phase 3 clinical trial evaluating Zoldonrasib for RAS G12D metastatic pancreatic cancer
RVMD - Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer